Security key
45719W205
Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT)
CUSIP: 45719W205
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock, $0.001 par value
- Total 13F shares
- 54,512,097
- Total 13F value
- $106,299,597
- Share change
- +3,040,159
- SEC-reported price per share
- $1.95
- Number of holders
- 48
- Value change
- +$5,482,917
- Number of buys
- 34
- Number of sells
- 29
- Shares outstanding
- 140,000,283
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
48
Top holders
10
IKT full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Previous quarter: Q1 2025
Inhibikase Therapeutics, Inc. SEC filings
Inhibikase Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 45719W205
Recent filing periods:
Ownership snapshot
Top reported holders of IKT - Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
Sands Capital Alternative...
Comparable rows
15/15
Latest evidence
31 Mar 2025
13D/G
13F
Lead comparable stake: 5%
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-6 of 15 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 5%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 5
ARMISTICE CAPITAL, LLC
5%
Sands Capital Alternatives, LLC
7.8%
Soleus Capital Management, L.P.
4.5%
Fairmount Funds Management LLC
4.4%
PERCEPTIVE ADVISORS LLC
4.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
|
$7,975,554
3,529,006 shares
|
$0 | 31 Dec 2024 |
| Sands Capital Alternatives, LLC |
13F
Company
|
7.8%
|
$23,980,500
10,950,000 shares
|
— | 31 Mar 2025 |
| Soleus Capital Management, L.P. |
13F
Company
|
4.5%
|
$13,851,750
6,325,000 shares
|
— | 31 Mar 2025 |
| Fairmount Funds Management LLC |
13F
Company
|
4.4%
|
$13,413,750
6,125,000 shares
|
— | 31 Mar 2025 |
| PERCEPTIVE ADVISORS LLC |
13F
Company
|
4.2%
|
$12,975,750
5,925,000 shares
|
— | 31 Mar 2025 |
| Commodore Capital LP |
13F
Company
|
3.8%
|
$11,704,306
5,344,432 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
48
Shares
54,512,097
Rows available
48
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
47
Q2 2025 holders
48
Holder diff
1
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend